Related Experiment Video
Updated: Nov 16, 2025
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment
Claudia Gulea1,2, Rosita Zakeri3, Vanessa Alderman4
1National Heart and Lung Institute, Imperial College London, Manresa Road, London, UK. c.gulea18@imperial.ac.uk.
Background:
Beta-blockers are associated with reduced mortality in patients with cardiovascular disease but are often under prescribed in those with concomitant COPD, due to concerns regarding respiratory side-effects. We investigated the effects of beta-blockers on outcomes in patients with COPD and explored within-class differences between different agents.
Methods:
We searched the Cochrane Central Register of Controlled Trials, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Medline for observational studies and randomized controlled trials (RCTs) investigating the effects of beta-blocker exposure versus no exposure or placebo, in patients with COPD, with and without cardiovascular indications. A meta-analysis was performed to assess the association of beta-blocker therapy with acute exacerbations of COPD (AECOPD), and a network meta-analysis was conducted to investigate the effects of individual beta-blockers on FEV1. Mortality, all-cause hospitalization, and quality of life outcomes were narratively synthesized.
Results:
We included 23 observational studies and 14 RCTs. In pooled observational data, beta-blocker therapy was associated with an overall reduced risk of AECOPD versus no therapy (HR 0.77, 95%CI 0.70 to 0.85). Among individual beta-blockers, only propranolol was associated with a relative reduction in FEV1 versus placebo, among 199 patients evaluated in RCTs. Narrative syntheses on mortality, all-cause hospitalization and quality of life outcomes indicated a high degree of heterogeneity in study design and patient characteristics but suggested no detrimental effects of beta-blocker therapy on these outcomes.
Conclusion:
The class effect of beta-blockers remains generally positive in patients with COPD. Reduced rates of AECOPD, mortality, and improved quality of life were identified in observational studies, while propranolol was the only agent associated with a deterioration of lung function in RCTs.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers